| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
DARMSTADT, Germany—Merck Serono, a division of Merck KGaA, announced Feb. 3 that it had signed a global agreement with ThresholdPharmaceuticals Inc., based in South San Francisco, Calif., to co-develop and commercializeTH-302, Threshold's small molecule hypoxia-targeted drug.
 
TH-302 is currentlybeing investigated in a global Phase III clinical trial in patients with soft-tissue sarcoma, a randomized Phase II trial in patients with advancedpancreatic cancer from which top-line results are expected in February, as wellas additional clinical studies in other solid tumors and hematologicalmalignancies.
 
 
Under the terms of the agreement, Merck willreceive co-development rights, exclusive global commercialization rights andwill provide Threshold an option to co-commercialize the therapeutic in theUnited States. In exchange, Threshold will receive an upfront payment of about $25 million and could receive up to around $35 million inadditional development milestones during 2012. Threshold is also eligible toreceive a $20 million milestone payment based on positiveresults from its randomized Phase II trial in pancreatic cancer.
 
 
In the United States, Threshold will have primaryresponsibility for development of TH-302 in the soft-tissue sarcoma indication.Threshold and Merck KGaA will jointly develop TH-302 in all other cancerindications being pursued. Merck KGaA will pay 70 percent of worldwide developmentcosts for TH-302.
 
Subject to FDA approval in the United States,Merck KGaA will initially be responsible for commercialization of TH-302 withThreshold receiving a tiered, double-digit royalty on sales. Under theroyalty-bearing portion of the agreement, Threshold retains the option toco-promote TH-302 in the United States. Additionally, Threshold retains theoption to co-commercialize TH-302 allowing the company to participate in up to50 percent of the profits in the United States, based on certain revenue tiers.Outside of the United States, Merck KGaA will be solely responsible for thecommercialization of TH-302 with Threshold receiving a tiered, double-digitroyalty on sales in these territories.
 
Reportedly, the deal is worth as much as $550 million to Threshold over the long run if everything falls into place.

"The addition of TH-302 to our pipelineprovides an important opportunity in several different tumor types to expandour oncology development program," said Susan Jane Herbert, head of global business development and strategy for Merck Serono. "Given the fact thatpancreatic cancer is a very difficult to treat indication, successful Phase IIresults could represent important upside for our company."
 
 
"We are excited by the new resources that ourpartnership is going to bring to the development of TH-302, and the expertisein clinical development and commercialization that Merck will contribute tothis program," said Barry Selick, president and CEO of Threshold. "Thiscollaboration provides Threshold a strong and committed partner with a sharedvision for TH-302."
 
 
TH-302 is a hypoxia-targeted drug that is thoughtto be activated under tumor hypoxic conditions, reportedly a hallmark for many cancerindications. Areas of low oxygen levelswithin tissues are common inmany solid tumors due to insufficient blood vessel growth. Similarly, the bonemarrow of patients with hematological malignancies has also been shown, in somecases, to be extremely hypoxic.
 
 
TH-302 has been investigated in more than 550 patientsin Phase I/II clinical trials to date in a broad spectrum of tumor types, bothas a monotherapy and in combination with chemotherapy treatments and othertargeted cancer drugs.
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue